Warnings, Columns-Drugs & Supplements, January 2005
January 15, 2005
| FDA Committees To Review Gastrointestinal, Cardiac Side Effects Of Celebrex, Bextra |
WASHINGTON, D.C. - A joint meeting of the U.S. Food and Drug Administration's Arthritis Drugs and Drug Safety & Risk Management committees on Feb. 16-18 will include a discussion of the risk-benefit profile for COX-2 selective nonsteroidal anti-inflammatory drugs.
Among the drugs to be discussed are Pfizer's Celebrex (celecoxib) and Bextra (valdecoxib).
In December, the National Cancer Institute and Pfizer halted a clinical trial of Celebrex for prevention of colon polyps after patients taking …
UPCOMING CONFERENCES
HarrisMartin's Mass Tort Settlements Conference - Sponsored by Milestone
June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo
HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates
May 29, 2024 - Salt Lake City, UT
The Grand America Hotel